FindTrial
Sign In

Effect of adjuvant Transarterial Chemoembolization (TACE) plus Lenvatinib on tumor recurrence in hepatocellular carcinoma (HCC) patients with microvascular invasion or portal vein tumour thrombus (Cheng's Classification I/II) following radical resection

Effect of adjuvant Transarterial Chemoembolization (TACE) plus Lenvatinib on tumor recurrence in hepatocellular carcinoma (HCC) patients with microvascular invasion or portal vein tumour thrombus (Cheng's Classification I/II) following radical resection: a single-center, prospective, non-randomized cohort study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040863
Enrollment
Unknown
Registered
2020-12-12
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

control group:TACE (transcatheter arterial chemoembolization)
experimental group:TACE combined with lenvatinib

Sponsors

Beijing Youan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Eligible patients were aged >= 18 years to 75 years; 2.Patients had histologically or cytologically confirmed HCC, and accepted radical resection; 3.Combined with microvascular invasion or portal vein tumour thrombus (Chengs Classification I/II); 4.Child-Pugh class A, score 5/6; 5.Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1; 6.Patients have signed informed consent form.

Exclusion criteria

Exclusion criteria: Pathology confirmed combined hepatocellular and cholangiocellular carcinoma or intrahepatic cholangiocarcinoma.

Design outcomes

Primary

MeasureTime frame
RFS (recurrence free survival);—

Secondary

MeasureTime frame
OS (overall survival);QoL (Quality-of-Life);—

Countries

China

Contacts

Public ContactGuangming Li

Beijing Youan Hospital, Capital Medical University

liguangming@ccmu.edu.cn+86 13501122244

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026